The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bayer; Bayer; Bayer; Bayer
 
Honoraria - Nestle Health Science; Nestle Health Science; Nestle Health Science; Nestle Health Science
Consulting or Advisory Role - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Honoraria - IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; Loxo; Loxo; Loxo; Loxo
Consulting or Advisory Role - Guidepoint Global; Guidepoint Global; Guidepoint Global; Guidepoint Global; OncoArt; OncoArt; OncoArt; OncoArt
Speakers' Bureau - SOLTI; SOLTI; SOLTI; SOLTI
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Kura Oncology (Inst); Kura Oncology (Inst); Kura Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Menarini (Inst); Menarini (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merus (Inst); Merus (Inst); Merus (Inst); Merus (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Synthon (Inst); Synthon (Inst); Synthon (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - START; START; START; START
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
 
Jordan Berlin
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Oncorena; Oncorena; Oncorena; Oncorena; Presagia; Presagia; Presagia; Presagia
Honoraria - Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Baxter; Baxter; Baxter; Baxter; Bayer; Bayer; Bayer; Bayer; Merrimack; Merrimack; Merrimack; Merrimack
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Alphasights; Alphasights; Alphasights; Alphasights; Axiom Biotechnologies; Axiom Biotechnologies; Axiom Biotechnologies; Axiom Biotechnologies; Baxter; Baxter; Baxter; Baxter; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Genentech; Genentech; Genentech; Genentech; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; GroupH; GroupH; GroupH; GroupH; Guidepoint Global; Guidepoint Global; Guidepoint Global; Guidepoint Global; Janssen; Janssen; Janssen; Janssen; Medscape; Medscape; Medscape; Medscape; Merrimack; Merrimack; Merrimack; Merrimack; Numab; Numab; Numab; Numab; Pfizer; Pfizer; Pfizer; Pfizer; Seagen; Seagen; Seagen; Seagen; Takeda; Takeda; Takeda; Takeda; Trieza Therapeutics; Trieza Therapeutics; Trieza Therapeutics; Trieza Therapeutics
Research Funding - Abbvie; Abbvie; Abbvie; Abbvie; Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Fate Therapeutics; Fate Therapeutics; Fate Therapeutics; Fate Therapeutics; Genentech; Genentech; Genentech; Genentech; Genmab; Genmab; Genmab; Genmab; Ignyta; Ignyta; Ignyta; Ignyta; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly; Lilly; Lilly; Lilly; Loxo; Loxo; Loxo; Loxo; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; miRNA Therapeutics; miRNA Therapeutics; miRNA Therapeutics; miRNA Therapeutics; Molecular Templates; Molecular Templates; Molecular Templates; Molecular Templates; MOLOGEN; MOLOGEN; MOLOGEN; MOLOGEN; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Seagen; Seagen; Seagen; Seagen; Takeda; Takeda; Takeda; Takeda
Travel, Accommodations, Expenses - Genmab; Genmab; Genmab; Genmab; Loxo; Loxo; Loxo; Loxo; miRNA Therapeutics; miRNA Therapeutics; miRNA Therapeutics; miRNA Therapeutics
 
John F. Deeken
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck; Merck; Merck; Merck
Patents, Royalties, Other Intellectual Property - UpToDate; UpToDate; UpToDate; UpToDate
 
Valentina Boni
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Zymeworks; Zymeworks; Zymeworks; Zymeworks
Research Funding - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Lilly; Lilly; Lilly; Lilly
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Takeda Science Foundation; Takeda Science Foundation; Takeda Science Foundation; Takeda Science Foundation
 
Shivani Nanda
Employment - Bayer; Bayer; Bayer; Bayer
 
Nicoletta Brega
Employment - Bayer; Bayer; Bayer; Bayer
 
Barrett H. Childs
No Relationships to Disclose
 
David Michael Hyman
Stock and Other Ownership Interests - Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Genentech; Genentech; Genentech; Genentech; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Loxo; Loxo; Loxo; Loxo; Puma Biotechnology; Puma Biotechnology; Puma Biotechnology; Puma Biotechnology
Travel, Accommodations, Expenses - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Genentech; Genentech; Genentech; Genentech
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Medscape; Medscape; Medscape; Medscape; MORE Health; MORE Health; MORE Health; MORE Health; OncLive; OncLive; OncLive; OncLive; Peerview; Peerview; Peerview; Peerview; PeerVoice; PeerVoice; PeerVoice; PeerVoice; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Research to Practice; Research to Practice; Research to Practice; Research to Practice; Targeted Oncology; Targeted Oncology; Targeted Oncology; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; BerGenBio; BerGenBio; BerGenBio; BerGenBio; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Helsinn Therapeutics; Helsinn Therapeutics; Helsinn Therapeutics; Helsinn Therapeutics; Hengrui Therapeutics; Hengrui Therapeutics; Hengrui Therapeutics; Hengrui Therapeutics; Ignyta; Ignyta; Ignyta; Ignyta; Lilly; Lilly; Lilly; Lilly; Loxo; Loxo; Loxo; Loxo; MORE Health; MORE Health; MORE Health; MORE Health; Pfizer; Pfizer; Pfizer; Pfizer; Takeda/Millennium; Takeda/Millennium; Takeda/Millennium; Takeda/Millennium; TP Therapeutics; TP Therapeutics; TP Therapeutics; TP Therapeutics; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences; Verastem; Verastem; Verastem; Verastem; Verastem; Verastem; Verastem; Verastem
Research Funding - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology); Wolters Kluwer (Royalties for Pocket Oncology); Wolters Kluwer (Royalties for Pocket Oncology); Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; PharmaMar; PharmaMar; PharmaMar; PharmaMar; Puma Biotechnology; Puma Biotechnology; Puma Biotechnology; Puma Biotechnology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teva; Teva; Teva; Teva